Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

Dianthus Therapeutics, Inc. /DE/

CIK 1690585 DNTH·Pharmaceutical Preparations · All EDGAR filings ↗

Material weakness Filing comparison

Dianthus Therapeutics, Inc. /DE/ reported internal control effective again after a material weakness

Material weakness in internal control Internal control reported effective

The weakness was first reported on 2024-03-21 — 718 days and 2 annual reports before this one.

GAAP. As of December 31, 2025, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in its 2023 Internal Control-Integrated Framework. Based on this assessment, our management concluded that our internal control over financial reporting was effective as of December 31, 2025. This Annual Report on Form 10-K does not include an attestation report of our independent registered…
Evidence
Current state
effective
Current state label
Internal control reported effective
Direction
remediated
Prior filed
2025-03-11
Prior form
10-K
Prior state
material_weakness
Prior state label
Material weakness in internal control
Remediation stated
No
Severity
normal
Source
Item 9A internal control conclusion, compared with the prior filing
Weakness annual reports
2
Weakness days reported
718
Weakness first reported
2024-03-21
Why
The company's conclusion on internal control over financial reporting changed: a material weakness was newly reported, or a previously reported one no longer appears.